Deconstructing the role of the ECM microenvironment on drug efficacy targeting MAPK signaling in a pre-clinical platform for cutaneous melanoma

Biomaterials

Volumn 56, Issue , 2015, Pages 129-139

  Blehm, Benjamin H ^a   Jiang, Nancy ^a   Kotobuki, Yorihisa ^a   Tanner, Kandice ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

3D hydrogels; Brain; Drug resistance; Hyaluronic acid; Metastasis; Microenvironment

Indexed keywords

ACID RESISTANCE; BRAIN; CELL ADHESION; CELL CULTURE; CELLS; CYTOLOGY; DERMATOLOGY; DRUG THERAPY; ENZYME ACTIVITY; ENZYME INHIBITION; HYDROGELS; ONCOLOGY; ORGANIC ACIDS; PATHOLOGY; TISSUE; TUMORS;

BRAIN METASTASIS; DRUG RESISTANCE; EXTRACELLULAR MATRICES; METASTASIS; METASTATIC DISEASE; METASTATIC LESIONS; MICROENVIRONMENTS; PATIENT SURVIVALS;

HYALURONIC ACID;

ARGINYLGLYCYLASPARTIC ACID; B RAF KINASE; CISPLATIN; DABRAFENIB; FIBRONECTIN; HYALURONIC ACID; LAMININ; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; ARGINYL-GLYCYL-ASPARTIC ACID; HYDROGEL; MACROGOL DERIVATIVE; OLIGOPEPTIDE;

ARTICLE; CELL ADHESION; CELL MOTILITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CUTANEOUS MELANOMA; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GENE MUTATION; HUMAN; HUMAN CELL; HYDROGEL; IC50; IN VIVO STUDY; MELANOMA CELL LINE; METASTASIS POTENTIAL; MOLECULAR MIMICRY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; BINDING SITE; BIOMIMETICS; BRAIN NEOPLASMS; CELL MOTION; CELL SURVIVAL; CHEMISTRY; DRUG SCREENING; MELANOMA; METABOLISM; METASTASIS; MOUSE; PATHOLOGY; SKIN NEOPLASMS; TUMOR CELL LINE;

ANIMALS; BINDING SITES; BIOMIMETICS; BRAIN NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; EXTRACELLULAR MATRIX; FIBRONECTINS; HUMANS; HYALURONIC ACID; HYDROGELS; LAMININ; MAP KINASE SIGNALING SYSTEM; MELANOMA; MICE; NEOPLASM METASTASIS; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; SKIN NEOPLASMS;

EID: 84928384445     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.03.041     Document Type: Article

References (61)

1. Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer 2003, 3:559-570.
2. Dummer R., Flaherty K.T. Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. Curr Opin Oncol 2012, 24:150-154.
3. Wagle N., Emery C., Berger M.F., Davis M.J., Sawyer A., Pochanard P., et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. JClin Oncol Off J Am Soc Clin Oncol 2011, 29:3085-3096.
4. Sanchez-Laorden B., Viros A., Girotti M.R., Pedersen M., Saturno G., Zambon A., et al. BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci Signal 2014, 7:ra30.
5. Egeblad M., Nakasone E.S., Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 2010, 18:884-901.
6. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. JCell Biol 2012, 196:395-406.
7. Mueller M.M., Fusenig N.E. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004, 4:839-849.
8. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
9. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., et al. Final version of 2009 AJCC melanoma staging and classification. JClin Oncol Off J Am Soc Clin Oncol 2009, 27:6199-6206.
10. Steeg P.S., Camphausen K.A., Smith Q.R. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer 2011, 11:352-363.
11. Posner J.B. Brain metastases: 1995. A brief review. JNeuro Oncol 1996, 27:287-293.
12. Menzies A.M., Long G.V., Murali R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Dev Ther 2012, 6:391-405.
13. Alcala A.M., Flaherty K.T. BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance. Clin Cancer Res Off J Am Assoc Cancer Res 2012, 18:33-39.
14. Hauschild A., Grob J.J., Demidov L.V., Jouary T., Gutzmer R., Millward M., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
15. Abbott N.J., Ronnback L., Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006, 7:41-53.
16. Eichler A.F., Chung E., Kodack D.P., Loeffler J.S., Fukumura D., Jain R.K. The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol 2011, 8:344-356.
17. Bissell M.J., Radisky D. Putting tumours in context. Nat Rev Cancer 2001, 1:46-54.
18. Villanueva J., Herlyn M. Melanoma and the tumor microenvironment. Curr Oncol Rep 2008, 10:439-446.
19. Rape A.D., Kumar S. Acomposite hydrogel platform for the dissection of tumor cell migration at tissue interfaces. Biomaterials 2014, 35:8846-8853.
20. Lee G.Y., Kenny P.A., Lee E.H., Bissell M.J. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 2007, 4:359-365.
21. Ulrich T.A., Jain A., Tanner K., MacKay J.L., Kumar S. Probing cellular mechanobiology in three-dimensional culture with collagen-agarose matrices. Biomaterials 2010, 31:1875-1884.
22. Tanner K. Regulation of the basement membrane by epithelia generated forces. Phys Biol 2012, 9:065003.
23. Morris E.J., Jha S., Restaino C.R., Dayananth P., Zhu H., Cooper A., et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov 2013, 3:742-750.
24. Wagle N., Van Allen E.M., Treacy D.J., Frederick D.T., Cooper Z.A., Taylor-Weiner A., et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov 2014, 4:61-68.
25. Grossman D., Altieri D.C. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 2001, 20:3-11.
26. Patsialou A., Bravo-Cordero J.J., Wang Y., Entenberg D., Liu H., Clarke M., et al. Intravital multiphoton imaging reveals multicellular streaming as a crucial component of invivo cell migration in human breast tumors. Intravital 2013, 2:e25294.
27. Laurent T.C., Fraser J.R.E. Hyaluronan. FASEB J 1992, 6:2397-2404.
28. Toole B.P. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004, 4:528-539.
29. Oikawa Y., Hansson J., Sasaki T., Rousselle P., Domogatskaya A., Rodin S., et al. Melanoma cells produce multiple laminin isoforms and strongly migrate on alpha 5 laminin(s) via several integrin receptors. Exp Cell Res 2011, 317:1119-1133.
30. Gaggioli C., Robert G., Bertolotto C., Bailet O., Abbe P., Spadafora A., et al. Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway. JInvest Dermatol 2007, 127:400-410.
31. Herlyn M., Thurin J., Balaban G., Bennicelli J.L., Herlyn D., Elder D.E., et al. Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res 1985, 45:5670-5676.
32. Tanner K., Mori H., Mroue R., Bruni-Cardoso A., Bissell M.J. Coherent angular motion in the establishment of multicellular architecture of glandular tissues. Proc Natl Acad Sci U S A 2012, 109:1973-1978.
33. Carbonell W.S., Ansorge O., Sibson N., Muschel R. The vascular basement membrane as "soil" in brain metastasis. PloS One 2009, 4:e5857.
34. Geiger B., Yamada K.M. Molecular architecture and function of matrix adhesions. Cold Spring Harb Perspect Biol 2011, 3.
35. Hersel U., Dahmen C., Kessler H. RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials 2003, 24:4385-4415.
36. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996, 12:697-715.
37. Hegerfeldt Y., Tusch M., Brocker E.B., Friedl P. Collective cell movement in primary melanoma explants: plasticity of cell-cell interaction, beta1-integrin function, and migration strategies. Cancer Res 2002, 62:2125-2130.
38. Falchook G.S., Long G.V., Kurzrock R., Kim K.B., Arkenau T.H., Brown M.P., et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379:1893-1901.
39. Smalley K.S., Haass N.K., Brafford P.A., Lioni M., Flaherty K.T., Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006, 5:1136-1144.
40. Roesch A., Vultur A., Bogeski I., Wang H., Zimmermann K.M., Speicher D., et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell 2013, 23:811-825.
41. Bernstein J.J., Woodard C.A. Glioblastoma cells do not intravasate into blood-vessels. Neurosurgery 1995, 36:124-132.
42. Tziampazis E., Kohn J., Moghe P.V. PEG-variant biomaterials as selectively adhesive protein templates: model surfaces for controlled cell adhesion and migration. Biomaterials 2000, 21:511-520.
43. Zhang M., Desai T., Ferrari M. Proteins and cells on PEG immobilized silicon surfaces. Biomaterials 1998, 19:953-960.
44. VandeVondele S., Voros J., Hubbell J.A. RGD-grafted poly-L-lysine-graft-(polyethylene glycol) copolymers block non-specific protein adsorption while promoting cell adhesion. Biotechnol Bioeng 2003, 82:784-790.
45. Yang F., Williams C.G., Wang D.A., Lee H., Manson P.N., Elisseeff J. The effect of incorporating RGD adhesive peptide in polyethylene glycol diacrylate hydrogel on osteogenesis of bone marrow stromal cells. Biomaterials 2005, 26:5991-5998.
46. Massia S.P., Hubbell J.A. An RGD spacing of 440 nm is sufficient for integrin alpha V beta 3-mediated fibroblast spreading and 140 nm for focal contact and stress fiber formation. JCell Biol 1991, 114:1089-1100.
47. Tokuda E.Y., Leight J.L., Anseth K.S. Modulation of matrix elasticity with PEG hydrogels to study melanoma drug responsiveness. Biomaterials 2014, 35:4310-4318.
48. Klemke R.L., Cai S., Giannini A.L., Gallagher P.J., deLanerolle P., Cheresh D.A. Regulation of cell motility by mitogen-activated protein kinase. JCell Biol 1997, 137:481-492.
49. Webb D.J., Donais K., Whitmore L.A., Thomas S.M., Turner C.E., Parsons J.T., et al. FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol 2004, 6:154.
50. Clark E.A., Hynes R.O. Ras activation is necessary for integrin-mediated activation of extracellular signal-regulated kinase 2 and cytosolic phospholipase A(2) but not for cytoskeletal organization. JBiol Chem 1996, 271:14814-14818.
51. Fidler I.J. The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 2011, 21:107-112.
52. Frischknecht R., Gundelfinger E.D. The brain's extracellular matrix and its role in synaptic plasticity. Adv Exp Med Biol 2012, 970:153-171.
53. Weigelt B., Lo A.T., Park C.C., Gray J.W., Bissell M.J. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat 2010, 122:35-43.
54. Loessner D., Stok K.S., Lutolf M.P., Hutmacher D.W., Clements J.A., Rizzi S.C. Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials 2010, 31:8494-8506.
55. Wang T.W., Spector M. Development of hyaluronic acid-based scaffolds for brain tissue engineering. Acta Biomater 2009, 5:2371-2384.
56. Pedron S., Becka E., Harley B.A. Regulation of glioma cell phenotype in 3D matrices by hyaluronic acid. Biomaterials 2013, 34:7408-7417.
57. Marklein R.A., Burdick J.A. Spatially controlled hydrogel mechanics to modulate stem cell interactions. Soft Matter 2010, 6:136-143.
58. Ananthanarayanan B., Kim Y., Kumar S. Elucidating the mechanobiology of malignant brain tumors using a brain matrix-mimetic hyaluronic acid hydrogel platform. Biomaterials 2011, 32:7913-7923.
59. Fridman R., Giaccone G., Kanemoto T., Martin G.R., Gazdar A.F., Mulshine J.L. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc Natl Acad Sci U S A 1990, 87:6698-6702.
60. Eke I., Storch K., Krause M., Cordes N. Cetuximab attenuates its cytotoxic and radiosensitizing potential by inducing fibronectin biosynthesis. Cancer Res 2013, 73:5869-5879.
61. Hendrix M.J., Seftor E.A., Kirschmann D.A., Quaranta V., Seftor R.E. Remodeling of the microenvironment by aggressive melanoma tumor cells. Ann N Y Acad Sci 2003, 995:151-161.